« Return to News | Drug Sponsors

HGS’s Benlysta grosses $59 million

Wednesday, January 11, 2012 11:05 AM

Benlysta (belimumab), the first approved drug for systemic lupus in 56 years, has already grossed $59.2 million, averaging $2.3 million in sales per week since it received FDA approval less than a year ago, according to Human Genome Sciences (HGS).

This treatment for adult patients with active, autoantibody-positive systemic lupus erythematosus (SLE) is quickly spreading, and has already been approved in Canada and at least eight European countries.

In December 2011, HGS and GlaxoSmithKline (GSK) announced that dosing of patients had been initiated in BLISS-SC, a phase III trial of the subcutaneous formulation of Benlysta. If this trial is successful and regulatory authorities agree, the subcutaneous formulation would make it possible for patients to self-administer Benlysta by injection once a week.

“We are pioneering a treatment in a market that has not seen a new option for patients in decades,” said H. Thomas Watkins, president and CEO of HGS. “Although we are still in the early adoption phase of our launch, our experience in the market to date reinforces our belief that Benlysta will ultimately play a major role in improving the standard of care for SLE patients.”

Share:          
CLINICAL TRIAL RESOURCES

Search:

NEWS ONLINE ARCHIVE

Browse by:

CWWeekly

December 17

Medici Global says its Alzheimer's Facebook page demonstrates the need for more early detection trials

Analysts: Expect more equity purchases of CROs in 2013

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

January 2013

Parexel celebrates 30 years of change, growth
CRO's founder and chairman reflects on challenges of the past, present and future

Strategies for increasing patient diversity in trials
Sponsors look to improve racial, ethnic recruitment without going overseas

Already a subscriber?
Log in to your digital subscription.

Purchase the January issue.

Subscribe to The CenterWatch Monthly.

December 2012

Publicity, regulation tightening reins on use of KOLs
Debate rages over need to revamp how sponsors use, pay medical experts

Time may be right to makeover the investigator brochure
Size, complexity prevent critical document from being thoroughly read

Already a subscriber?
Log in to your digital subscription.

Purchase the December issue.

Subscribe to The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs

More Jobs

 

Copyright © 1995-2013 CenterWatch.